drugset
drugset / Trial / NCT02244021

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

NCT02244021 ↗

Phase 2 Completed 13 enrolled Fondazione Italiana Linfomi - ETS
NaSingle-groupOpen-labelTreatment

Summary

A pilot phase II study with brentuximab vedotin as pre-ASCT induction therapy in relapsed/refractory Hodgkin's lymphoma patients non-responding to IGEV salvage treatment.

Timeline

Start
2014-12
Primary completion
2016-07
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Brentuximab Vedotin Monoclonal antibody 1.8 mg/kg Intravenous

Indications

Hodgkins lymphoma